Amicus Therapeutics (NASDAQ: FOLD) and Dr.Reddy's Laboratories (NYSE:RDY) are both mid-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, profitability, analyst recommendations, valuation, risk, dividends and institutional ownership.
Dr.Reddy's Laboratories pays an annual dividend of $0.29 per share and has a dividend yield of 0.9%. Amicus Therapeutics does not pay a dividend. Dr.Reddy's Laboratories pays out 31.2% of its earnings in the form of a dividend.
Amicus Therapeutics has a beta of 1.45, meaning that its share price is 45% more volatile than the S&P 500. Comparatively, Dr.Reddy's Laboratories has a beta of 0.23, meaning that its share price is 77% less volatile than the S&P 500.
This is a breakdown of recent ratings and recommmendations for Amicus Therapeutics and Dr.Reddy's Laboratories, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Amicus Therapeutics currently has a consensus target price of $19.50, indicating a potential upside of 31.67%. Dr.Reddy's Laboratories has a consensus target price of $30.51, indicating a potential downside of 10.32%. Given Amicus Therapeutics’ stronger consensus rating and higher probable upside, analysts clearly believe Amicus Therapeutics is more favorable than Dr.Reddy's Laboratories.
This table compares Amicus Therapeutics and Dr.Reddy's Laboratories’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Institutional & Insider Ownership
13.9% of Dr.Reddy's Laboratories shares are held by institutional investors. 3.4% of Amicus Therapeutics shares are held by company insiders. Comparatively, 2.0% of Dr.Reddy's Laboratories shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Valuation & Earnings
This table compares Amicus Therapeutics and Dr.Reddy's Laboratories’ revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Amicus Therapeutics||$4.96 million||496.46||-$200.04 million||($1.83)||-8.09|
|Dr.Reddy's Laboratories||$2.17 billion||2.60||$186.00 million||$0.93||36.58|
Dr.Reddy's Laboratories has higher revenue and earnings than Amicus Therapeutics. Amicus Therapeutics is trading at a lower price-to-earnings ratio than Dr.Reddy's Laboratories, indicating that it is currently the more affordable of the two stocks.
Dr.Reddy's Laboratories beats Amicus Therapeutics on 9 of the 16 factors compared between the two stocks.
About Amicus Therapeutics
Amicus Therapeutics, Inc. is a biotechnology company. The Company is engaged in the discovery, development and commercialization of a set of treatments for patients living with devastating rare and orphan diseases. Its lead product, migalastat HCl is a small molecule that can be used as a monotherapy and in combination with enzyme replacement therapy (ERT) for Fabry disease. Its pipeline also includes SD-101, which is a product candidate in late-stage development, as a potential first-to-market therapy for the chronic, rare connective tissue disorder Epidermolysis Bullosa (EB). It is also leveraging its Chaperone-Advanced Replacement Therapy (CHART) platform technologies to develop ERT products for Pompe disease, Fabry disease, and potentially other lysosomal storage disorders (LSDs). The Company is also investigating preclinical and discovery programs in other rare and devastating diseases, including cyclin-dependent kinase-like 5 (CDKL5) deficiency.
About Dr.Reddy's Laboratories
Dr. Reddy’s Laboratories Limited is a pharmaceutical company that is engaged in providing medicines. The Company operates in three segments: Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Proprietary Products. The Global Generics segment includes manufacturing and marketing prescription and over-the-counter finished pharmaceutical products ready for consumption by the patient, marketed under a brand name (branded formulations) or as generic finished dosages with therapeutic equivalence to branded formulations (generics). PSAI segment includes the Company’s business of manufacturing and marketing active pharmaceutical ingredients and intermediates (API) or bulk drugs. Proprietary Products segment focuses on the research, development and manufacture of differentiated formulations and new chemical entities. These products fall within the dermatology and neurology therapeutic areas, and are marketed and sold through its subsidiary, Promius Pharma, LLC.
Receive News & Ratings for Amicus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amicus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.